Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer

乳腺癌 有效载荷(计算) 医学 癌症研究 结合 计算生物学 乳腺癌转移 后天抵抗 靶向治疗 疾病 生物信息学 癌症 生物 转移 多元化(营销策略) 发病机制 肿瘤科 内科学 串扰 癌症治疗
作者
Dileep Reddy. Rampa,Minji Seo,Nanae Ogata,Zhaoxuan Yang,Nithya Sridhar,Fujii Takeo,Chalothorn Wannaphut,Jennifer A. Maynard,Kyoji Tsuchikama,George W. Sledge,Naoto T. Ueno,Jangsoon Lee
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:32 (8): 1454-1461 被引量:4
标识
DOI:10.1158/1078-0432.ccr-25-3321
摘要

PURPOSE: Antibody-drug conjugates (ADC) have transformed the treatment of breast cancer. FDA-approved ADC such as trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG), and datopotamab deruxtecan (Dato-DXd) have demonstrated clinical benefit; however, drug resistance will almost inevitably emerge in the metastatic setting, and there is no established strategy for selecting subsequent ADC after disease progression following the first exposure to the ADC. This study aimed to define mechanisms of acquired resistance and evaluate rational sequencing approaches. EXPERIMENTAL DESIGN: We generated breast cancer cell lines resistant to T-DXd (TDXd-R) and SG (SG-R). We assessed antigen expression, internalization, and resistance pathways, including efflux transporter activity. To identify therapeutic strategies, we tested the efficacy of ADC carrying non-topoisomerase I (Topo1) payloads in in vitro and in vivo models. RESULTS: Resistance in both TDXd-R and SG-R models was primarily mediated by payload-specific factors, notably upregulation of efflux transporters, rather than loss of antigen expression. Switching to ADC with mechanistically different payloads, including microtubule inhibitors, restored antitumor activity in vitro and in vivo. CONCLUSIONS: Cross-resistance to sequential ADC is primarily driven by shared payload mechanisms rather than loss of the target. Our data also suggest that the clinical benefit of sequential Topo1-based ADC may be reduced following disease progression on a Topo1-based ADC, likely due to these shared resistance pathways. Importantly, switching to ADC with non-cross-resistant payload classes may offer a more effective approach to guide ADC sequencing in patients with metastatic breast cancer, supporting payload diversification as a clinically actionable strategy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
西柚子完成签到 ,获得积分20
2秒前
Samuel应助owlhealth采纳,获得20
2秒前
馥桉樊完成签到 ,获得积分10
3秒前
卓奕雯完成签到 ,获得积分10
3秒前
123456qi完成签到,获得积分10
4秒前
张zhang发布了新的文献求助10
4秒前
xinjiasuki完成签到 ,获得积分10
4秒前
4秒前
5秒前
yy发布了新的文献求助10
5秒前
李wf完成签到,获得积分10
7秒前
迷路的忆之完成签到,获得积分10
7秒前
燕子发布了新的文献求助10
7秒前
溯7完成签到,获得积分10
8秒前
梦梦完成签到,获得积分10
9秒前
小蘑菇应助wys2493采纳,获得10
10秒前
dakjdia完成签到,获得积分10
10秒前
bin完成签到,获得积分10
11秒前
小铁匠发布了新的文献求助10
11秒前
nonory完成签到,获得积分10
14秒前
AA完成签到,获得积分10
16秒前
penghuiye完成签到,获得积分10
16秒前
Akim应助粗暴的涵蕾采纳,获得10
17秒前
马嘉祺完成签到,获得积分10
17秒前
斯文败类应助燕子采纳,获得20
18秒前
遨游的小鱼完成签到 ,获得积分10
20秒前
20秒前
PDIF-CN2完成签到,获得积分10
20秒前
orixero应助小铁匠采纳,获得10
21秒前
秦奥洋完成签到,获得积分10
21秒前
JamesPei应助舒适念瑶采纳,获得10
21秒前
可可完成签到,获得积分10
22秒前
风趣的苑博完成签到,获得积分10
22秒前
yliu完成签到,获得积分10
23秒前
lanse完成签到,获得积分20
23秒前
tyj发布了新的文献求助10
23秒前
67号完成签到 ,获得积分10
23秒前
科研通AI6.3应助yy采纳,获得10
24秒前
会赢完成签到 ,获得积分10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场规模及竞争格局分析报告 1000
48V Low-voltage Power Distribution Network (PDN) Architecture Industry Report, 2024 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 610
适配Micro-LED色转换的高兼容性量子点负性光刻胶制备与工艺研究 500
Direct and Iterative Linear System Solvers 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7312778
求助须知:如何正确求助?哪些是违规求助? 8929267
关于积分的说明 18924483
捐赠科研通 6973336
什么是DOI,文献DOI怎么找? 3213476
关于科研通互助平台的介绍 2381597
邀请新用户注册赠送积分活动 2191537